Rolipram treatment during consolidation ameliorates long-term object location memory in aged male mice.
Aging
CREB
Hippocampus
PDE4
Spatial memory
cAMP
Journal
Neurobiology of learning and memory
ISSN: 1095-9564
Titre abrégé: Neurobiol Learn Mem
Pays: United States
ID NLM: 9508166
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
11
08
2019
revised:
08
01
2020
accepted:
16
01
2020
pubmed:
22
1
2020
medline:
20
1
2021
entrez:
22
1
2020
Statut:
ppublish
Résumé
Normal aging is accompanied by cognitive and memory impairments that negatively impact quality of life for the growing elderly population. Hippocampal function is most vulnerable to the deleterious effects of aging, and deficits in hippocampus-dependent memories are common amongst aged individuals. Moreover, signaling networks such as the cAMP/PKA/CREB pathway, which are critical for memory consolidation, are dampened in healthy aged subjects. Phosphodiesterase (PDE) enzymes that break down cAMP are also affected by aging, and increased break down of cAMP by PDEs may contribute to reduced activity of the cAMP/PKA/CREB signaling network in the brain of aged individuals. Here, we report that the PDE4 inhibitor rolipram administered during consolidation of hippocampus-dependent object location memory improves aged-related spatial memory deficits in aged mice.
Identifiants
pubmed: 31962134
pii: S1074-7427(20)30012-5
doi: 10.1016/j.nlm.2020.107168
pmc: PMC7106430
mid: NIHMS1551654
pii:
doi:
Substances chimiques
Phosphodiesterase 4 Inhibitors
0
Rolipram
K676NL63N7
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107168Subventions
Organisme : NIA NIH HHS
ID : P01 AG017628
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG062398
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007953
Pays : United States
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Mech Ageing Dev. 1981 Mar;15(3):239-42
pubmed: 6265714
Pharmacol Biochem Behav. 2015 Aug;135:70-82
pubmed: 26046533
Neurobiol Learn Mem. 2014 Dec;116:90-95
pubmed: 25242102
Behav Brain Res. 1997 Nov;88(2):181-93
pubmed: 9404627
Neurobiol Learn Mem. 2004 Jan;81(1):19-26
pubmed: 14670355
Neurobiol Learn Mem. 2014 Mar;109:122-30
pubmed: 24380868
Brain Res. 2001 Jun 8;903(1-2):86-93
pubmed: 11382391
Eur J Pharmacol. 2010 May 25;634(1-3):95-100
pubmed: 20223232
Neurobiol Learn Mem. 2008 Oct;90(3):569-75
pubmed: 18558503
Neuropsychopharmacology. 2009 Jul;34(8):1914-25
pubmed: 19262466
Learn Mem. 1998 Sep-Oct;5(4-5):365-74
pubmed: 10454361
Neuropharmacology. 2015 Aug;95:361-6
pubmed: 25896769
Neurobiol Aging. 2008 Oct;29(10):1533-46
pubmed: 17478013
Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):15020-5
pubmed: 9844008
Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5280-5
pubmed: 10220457
Elife. 2017 Jan 04;6:
pubmed: 28051768
J Alzheimers Dis. 2013;35(2):413-21
pubmed: 23422357
Brain Res. 1978 Jan 6;139(1):169-77
pubmed: 202373
Nat Rev Mol Cell Biol. 2001 Aug;2(8):599-609
pubmed: 11483993
Neuroscience. 2007 Dec 5;150(2):260-72
pubmed: 18029102
Biomed Pharmacother. 2017 Apr;88:698-707
pubmed: 28152479
J Neurosci. 2014 Nov 19;34(47):15715-21
pubmed: 25411499
Neuroscience. 1992;46(2):475-88
pubmed: 1347408
J Neurosci. 2008 Oct 1;28(40):9910-9
pubmed: 18829949
Nat Neurosci. 2012 Jul 01;15(8):1111-3
pubmed: 22751036
Learn Mem. 2010 Feb 26;17(3):155-60
pubmed: 20189960
Cell Signal. 2018 Jan;42:281-291
pubmed: 29175000
Exp Gerontol. 2018 Jun;106:222-231
pubmed: 29524468
Neurobiol Aging. 2012 Sep;33(9):2220-4
pubmed: 21872364
Exp Brain Res. 1997 Mar;113(3):509-19
pubmed: 9108217
J Neurosci. 2001 Apr 1;21(7):2404-12
pubmed: 11264314
Neurosci Biobehav Rev. 2017 Aug;79:66-86
pubmed: 28476525
Brain Res. 2005 Aug 23;1054(1):30-7
pubmed: 16054117
Neurobiol Aging. 1989 Jan-Feb;10(1):31-43
pubmed: 2569170
Mol Brain. 2012 May 14;5:14
pubmed: 22583753
J Pharmacol Sci. 2005 Jul;98(3):191-7
pubmed: 15968141
Ageing Res Rev. 2015 Nov;24(Pt B):232-62
pubmed: 26318058
J Neurosci. 2010 Apr 7;30(14):5037-46
pubmed: 20371824
J Comp Physiol Psychol. 1979 Feb;93(1):74-104
pubmed: 221551
Am J Geriatr Psychiatry. 2019 Mar;27(3):213-236
pubmed: 30686664
Neuropsychopharmacology. 2014 Dec;39(13):2938-48
pubmed: 24964813
Learn Mem. 2002 Mar-Apr;9(2):58-65
pubmed: 11992016
Neuroscience. 2013 Feb 12;231:182-94
pubmed: 23238576
Brain Res. 2007 Apr 13;1141:214-7
pubmed: 17303091
J Pharmacol Exp Ther. 2011 Aug;338(2):641-7
pubmed: 21566211
Learn Mem. 2007 May 03;14(5):350-8
pubmed: 17522026
Curr Alzheimer Res. 2010 May;7(3):197-9
pubmed: 20088811
Curr Pharm Des. 2015;21(3):365-77
pubmed: 25159076
Neurobiol Aging. 1984 Spring;5(1):43-8
pubmed: 6738785
Physiol Rev. 2011 Apr;91(2):651-90
pubmed: 21527734
Neuropharmacology. 2018 Aug;138:151-159
pubmed: 29885420
Neurosci Lett. 2006 Sep 11;405(1-2):142-6
pubmed: 16854527
Neurosci Lett. 2001 Nov 23;315(1-2):89-92
pubmed: 11711222
Ageing Res Rev. 2005 May;4(2):123-40
pubmed: 15964248
Hippocampus. 2014 Mar;24(3):270-9
pubmed: 24132946
J Alzheimers Dis. 2014;42 Suppl 4:S561-73
pubmed: 25125473
Cell. 1994 Oct 7;79(1):59-68
pubmed: 7923378
Curr Drug Targets CNS Neurol Disord. 2005 Oct;4(5):481-97
pubmed: 16266283
Neurotherapeutics. 2015 Jan;12(1):29-41
pubmed: 25575647
Annu Rev Psychol. 2009;60:173-96
pubmed: 19035823